
Opinion|Videos|February 28, 2025
Patient-Centered Selection of BTK Inhibitors: Balancing Clinical Factors and Patient Preferences
Panelists discuss how clinical and patient-specific factors, such as comorbidities, age, and risk profiles, influence the selection of Bruton tyrosine kinase (BTK) inhibitors for treatment-naive patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) while also considering how these factors align or differ from patient preferences regarding treatment duration, adverse effect profiles, and lifestyle impact.
Advertisement
Episodes in this series

- What clinical and patient-specific factors influence your treatment selection between BTK inhibitors for treatment-naive patients with CLL and MCL?
- How do your factors align with or differ from your patients’ preferences and values?
Advertisement
Related to this article

SaTScan detects an acute HCV outbreak cluster in California, showing the potential of automated surveillance, though real-time testing is needed.

The editor in chief of Evidence-Based Oncology, who was recently named medical director of Precision Medicine for The US Oncology Network, discussed milestones met and those still to be achieved.

Genetic analysis finds 125 loci shared by insomnia and CRP, with Mendelian randomization favoring an effect from insomnia liability to inflammation.

Cleveland roundtable panelists across 4 disease states name access, not evidence, as the shared barrier to care.

Alice Hall-Partyka, JD, a partner at Crowell & Moring explains the lawsuits challenging CMS' Medicaid rule on pediatric gender care and its legal weak points.

Siva Mohan, MD, explains how drug costs drive silent nonadherence, PA burden, and biosimilar hesitancy, and what payers can do about it.
Advertisement
Advertisement
Trending on AJMC
1
PBM Reform and Supportive Care Needs: Nicolas Ferreyros
2
5 Things to Know About the One Big Beautiful Bill Act
3
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
4
Roundtable Wrap: Cleveland's Tech Is Ready, Access Isn't
5





